---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-036052"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T16:11:23.167120+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Imara supplements merger proxy with lawsuit update and executive compensation details

## Summary
- Lawsuit filed Nov 23, 2022 voluntarily dismissed Jan 19, 2023; Imara says meritless.
- Pipeline chart updated: ELVN-002 advanced to Phase 1 clinical trial.
- SVB Securities received $2.2M fees from Imara in past 2 years; disclosed as supplemental.
- Post-merger: Kintz base salary to $550K, Collins to $465K, Hohl to $410K; bonus targets increased.
- Enliven executives to receive change-in-control severance with 12-18 months salary and equity vesting.

## SEC filing metadata
- accession: 0001193125-23-036052
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312523036052/0001193125-23-036052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312523036052/d410339d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-036052
- JSON: https://secwatch.observer/filing/0001193125-23-036052.json
- Plain text: https://secwatch.observer/filing/0001193125-23-036052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.